Abstract
We have examined the methylation profiles of the asparagine synthetase (ASY) promoter in a number of human leukemic cell lines in relation to their asparagine (ASN) requirements in vitro. Cells in which the promoter is highly methylated are auxotrophs and express ASY at very low levels. Electromobility shift assays (EMSA) of nuclear extracts with oligomers from the promoting region show, in addition to recognized transcription factor binding, a novel methyl binding protein specific for a 12 base consensus sequence, which includes a single methylated CpG. This sequence overlaps that of the amino-acid response unit of the ASY promoter, which is activated byATF4 and C/EBP. Competition by the methyl binding protein could account for the observed failure of the methylated promoter to bind these transcription factors and consequently, although other mechanisms can also be operative, for the specific repression of the gene. The ASY methyl binding protein (ASMB) is present in leukemic lymphoid and myeloid cells irrespective of their methylation status, and in normal lymphocytes after phytohemagglutinin stimulation. It has been purified by affinity chromatography and has a molecular size of 40 kDa in 10% SDS-polyacrylamide gels.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andrulis IL, Chen J and Ray PN . (1987). Mol. Cell Biol., 7, 2435–2443.
Balestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, Cigudosa JC, Huang TH and Esteller M . (2003). EMBO J., 22, 6335–6345.
Bird A . (2002). Genes Dev., 16, 6–21.
Bird AP and Wolffe AP . (1999). Cell, 99, 451–454.
Boyd KE, Wells J, Bartley SM and Farnham PJ . (1998). Proc. Natl. Acad. Sci., 95, 13887–13892.
Broome JD . (1963). J. Exp. Med., 118, 99–148.
Broome JD . (1968). J. Exp. Med., 127, 1055–1072.
Daniel JM, Spring CM, Crawford HC, Reynolds AB and Baig A . (2002). Nucleic Acids Res., 30, 2911–2919.
Dignam JD, Lebovitz RM and Roeder RG . (1983). Nucleic Acids Res., 5, 1475–1489.
Drexler HG . (2001). The Leukemia-Lymphoma Cell Line Facts Book. Academic Press: New York.
Ehrlich M and Ehrlich KC . (1993). DNA Methylation: Molecular Biology and Biological Significance. Jost JP and Saluz HP (eds). Birkhauser Verlag: Basel, pp 145–168.
Feng Q and Zhang Y . (2001). Genes Dev., 15, 827–832.
Fuks F, Hurd PJ, Deplos RH and Kouzarides T . (2003). Nucleic Acids Res., 31, 2305–2312.
Greco A, Gong SS, Ittmann M and Basilico C . (1989). Mol. Cell Biol., 9, 2350–2359.
Guerrini L, Gong SS, Mangasarian K and Basilico C . (1993). Mol. Cell Biol., 13, 3202–3212.
Hendrich B and Bird A . (1998). Mol. Cell Biol., 18, 6538–6547.
Holler M, Westin G, Jiricny J and Schaffner W . (1988). Genes Dev., 2, 1127–1135.
Jones PA . (2002). Oncogene, 21, 5358–5360.
Jones PL, Veenstva GJ, Wade PA, Vermaak D, Landsberger N, Strouboulis J and Wolfe AP . (1998). Nat. Genet., 19, 187–191.
Jost JP and Hofsteenge J . (1992). Proc. Natl. Acad. Sci., 89, 9499–9503.
Jost JP and Saluz HP . (1993). DNA Methylation: Molecular Biology and Biological Significance, Jost JP and Saluz HP (eds). Birkhauser Verlag: Basel, pp 425–451.
Khan R, Zhang XY, Supakar PC, Ehrlich KC and Ehrlich M . (1988). J. Biol. Chem., 263, 14374–14383.
Matheson EC and Hall AG . (2003). Carcinogenesis, 24, 31–38.
Meehan RR, Lewis JD, McKay S, Kleiner EL and Bird AP . (1989). Cell, 58, 499–507.
Nan X, Meehan RR and Bird A . (1993). Nucleic Acids Res., 21, 4886–4892.
Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD and Sakai T . (1993). Oncogene, 8, 1063–1067.
Peng H, Shen N, Qian L, Sun XL, Koduru P, Godwin LO, Issa JP and Broome JD . (2001). Br. J. Cancer, 85, 930–935.
Ramji DP and Foka P . (2002). Biochem. J., 365 (Part 3), 561–575.
Sengupta PK, Ehrlich M and Smith BD . (1999). J. Biol. Chem., 274, 36649–36655.
Siu F, Bain PJ, LeBlanc-Chaffin R, Chen H and Kilberg MS . (2002). J. Biol. Chem., 277, 24120–24127.
Siu F, Chen C, Zhong C and Kilberg MS . (2001). J. Biol. Chem., 276, 48100–48107.
Wade PA . (2001). Oncogene, 20, 3166–3173.
Yoon HG, Chan DW, Reynolds AB, Qin J and Wong J . (2003). Mol. Cell, 12, 723–734.
Zhong XY, Jabrane-Ferrat N, Asiedu CK, Samac S, Peterlin BM and Ehrlich M . (1993). Mol. Cell. Biol., 13, 6810–6818.
Zhong C, Chen C and Kilberg MS . (2003). Biochem. J., 372 (Part 2), 603–609.
Acknowledgements
The secretarial assistance of Ms Edda Morgan-Boncy is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ren, Y., Roy, S., Ding, Y. et al. Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein. Oncogene 23, 3953–3961 (2004). https://doi.org/10.1038/sj.onc.1207498
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207498
Keywords
This article is cited by
-
Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical
BioDrugs (2023)
-
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
Cell Death & Disease (2021)
-
Asparaginase pharmacology: challenges still to be faced
Cancer Chemotherapy and Pharmacology (2017)
-
Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines
Scientific Reports (2015)
-
Methylation analysis of asparagine synthetase gene in acute lymphoblastic leukemia cells
Leukemia (2006)
